文献速递免疫规划传染病防控与疫情报告

10价和13价肺炎球菌结合疫苗对欧洲儿童侵袭性肺炎球菌病的有效性:SpIDnet观察性多中心研究

Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
PubMed 文献 · Vaccine · 2022-05-28

SpIDnet多中心观察性研究比较2012-2018年欧洲儿童中PCV10/PCV13血清型IPD病例与非PCV13血清型IPD对照的接种状态。≥1剂PCV13对PCV13血清型有效性为84.2%(95%CI:79.0-88.1),≥1剂PCV10对PCV10血清型有效性为84.8%(69.4-92.5)。PCV13对3型和6C有保护,PCV10对19A和6C有效性不显著,PCV13有效性随加强接种后时间下降。

要点

  • ≥1剂PCV13对PCV13血清型IPD有效性84.2%(95%CI:79.0-88.1)。
  • ≥1剂PCV10对PCV10血清型IPD有效性84.8%(95%CI:69.4-92.5)。
  • PCV10对19A和6C有效性不显著,PCV13对3型和6C有保护。

核心结论

  • PCV10和PCV13对各自疫苗血清型组IPD提供相似保护,但血清型特异性有效性因血清型和疫苗而异。
  • PCV13对3型和疫苗相关血清型6C IPD提供个体保护。
  • PCV10对疫苗相关血清型19A和6C的有效性不显著。
  • PCV13有效性随加强接种后时间下降。
  • 该多国研究能以国家层面罕见的精度测量血清型特异性疫苗有效性,此类大型网络对疫苗上市后评价至关重要。

研究设计与样本

  • SpIDnet观察性多中心研究,比较PCV10和PCV13血清型IPD病例与非PCV13血清型IPD对照在2012-2018年的接种状态。
  • PCV13研究纳入来自十个研究点的2522例IPD病例,PCV10研究纳入来自四个研究点的486例病例。
  • 合并有效性计算公式为(1-接种比值比)×100,并测量加强接种后随时间变化的有效性。

主要发现

  • ≥1剂PCV13对PCV13血清型(n=2353)的有效性为84.2%(95%CI:79.0-88.1)。
  • PCV13有效性从加强接种后<12个月的93.1%(87.8-96.1)下降至≥24个月的85.1%(72.0-92.1)。
  • ≥1剂PCV13对致命性PCV13 IPD有效性为84.7%(55.7-94.7),对3型、19A和1型分别为64.5%(43.7-77.6)、83.2%(73.7-89.3)和85.1%(67.6-93.1),对6C为85.4%(62.3-94.4)。
  • 3型和19A的有效性下降更快。
  • ≥1剂PCV10对PCV10血清型(n=370)有效性为84.8%(69.4-92.5),对1型和7F分别为27.2%(-187.6至81.6)和85.3%(35.2-96.7),对疫苗相关血清型19A和6C分别为32.5%(-28.3至64.5)和-14.4%(-526.5至79.1)。

关键数值与推荐

  • ≥1剂PCV13对PCV13血清型IPD有效性84.2%(95%CI:79.0-88.1)。
  • ≥1剂PCV13对3型、19A、1型和6C有效性分别为64.5%(43.7-77.6)、83.2%(73.7-89.3)、85.1%(67.6-93.1)和85.4%(62.3-94.4)。
  • ≥1剂PCV10对PCV10血清型IPD有效性84.8%(95%CI:69.4-92.5)。
  • PCV10对19A和6C有效性分别为32.5%(-28.3至64.5)和-14.4%(-526.5至79.1),未达统计学显著。

临床怎么用

  • PCV10和PCV13对各自疫苗血清型组IPD提供相似保护。
  • PCV13对3型和疫苗相关血清型6C IPD提供个体保护。
  • PCV10对疫苗相关血清型19A和6C的有效性不显著。
  • PCV13有效性随加强接种后时间下降,3型和19A下降更快。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). METHODS: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. RESULTS: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. CONCLUSIONS: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022. PMID: 35637067. doi:10.1016/j.vaccine.2022.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。